Skip to content

Omega Tots: A Randomized, Controlled Trial of Long-chain Polyunsaturated Fatty Acid Supplementation of Toddler Diets and Developmental Outcomes

Omega Tots: A Randomized, Controlled Trial of Long-chain Polyunsaturated Fatty Acid Supplementation of Toddler Diets and Developmental Outcomes

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01576783
Enrollment
377
Registered
2012-04-12
Start date
2012-04-26
Completion date
2017-04-06
Last updated
2021-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Child Development, Preterm Birth

Brief summary

The purpose of this study is to examine whether supplementation with certain polyunsaturated fatty acids can help the cognitive development of children born preterm.

Interventions

200 mg DHA+ 200 mg AA per day for 6 months

DIETARY_SUPPLEMENTPlacebo

400 mg corn oil per day for 6 months

Sponsors

Allen Foundation Inc.
CollaboratorOTHER
March of Dimes
CollaboratorOTHER
Cures Within Reach
CollaboratorOTHER
Health Resources and Services Administration (HRSA)
CollaboratorFED
Sarah Keim
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
10 Months to 16 Months
Healthy volunteers
No

Inclusion criteria

1. Age 10-16 completed months (age corrected for prematurity) at baseline 2. Discontinued regular breastfeeding and formula feeding at the time of randomization 3. Gestational age \< 35 completed weeks at birth 4. English is primary language in home 5. Informed consent obtained and signed 6. Child admitted to any NCH managed NICU or children who have ever had a Neonatology Clinic follow up visit scheduled, regardless of attendance

Exclusion criteria

1. Feeding problems 2. Major malformation, metabolic, or digestive disorder that would preclude participation and/or optimal absorption of the supplement. 3. Weight \< 5th or \> 95th percentile for age, per WHO growth charts 4. Consume DHA supplement drops, chews, or powders or Pediasure, or fatty fish more than 2x per week 5. Plans to move out of the area within the next 6 months 6. Known corn allergy 7. Known soy allergy 8. Known fish allergy

Design outcomes

Primary

MeasureTime frameDescription
Erythrocyte Fatty Acid LevelsBaseline to 180 days post-randomizationThis outcome measure involved an examination of change in plasma and RBC fatty acid concentrations from the first study visit to the final study visit. The changes were calculated as the fatty acid level at 180 days minus the fatty acid level at baseline. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc
Erythrocyte Fatty Acid Levels (Additional Data)Baseline to 180 days post-randomizationThis outcome measure involved an examination of change in plasma and RBC fatty acid concentrations from the first study visit to the final study visit. The changes were calculated as the fatty acid level at 180 days minus the fatty acid level at baseline. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc
Enrollment and Trial CompletionBaseline to 180 days post-randomizationThe number of children who enroll in the trial and the number of those children who return for study visits 2 and 3. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc.
AdherenceBaseline to 180 days post-randomizationThe mean (average) percentage of packets consumed by the children assigned to the supplement or placebo. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc

Secondary

MeasureTime frameDescription
(Behavior) Infant Behavior Questionnaire-Revised (IBQ-R; Short Form)Baseline to 180 days post-randomizationInfant Behavior Questionnaire-Revised (IBQ-R; short form) was used to assess effortful control (12 items) and activity level (3 items). The IBQ-R measures early temperament-based inhibitory control,a key component of executive function as children mature. Scores range from 1 to 7, with higher scores indicating greater frequency of behaviors. IBQ-R scores were measured at baseline and then again at study completion (180 days post randomization). The scores were calculated as a change between two time points (the IBQ-R value at 180 days minus the IBQ-R value at baseline).
(Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III)Baseline to 180 days post-randomizationBayley Scales of Infant and Toddler Development, third edition, (Bayley-III) is an instrument designed to measure the developmental functioning of infants and toddlers between the ages of 1 month and 42 months (age adjustments for prematurity are accommodated with the tool). It provides age specific composite scores for cognitive (91 items,score min 55 max 145), language (98 items, score min 47 max 153), and motor (138 items, score min 46 max 154) skills. For all scales, higher scores are better and lower scores indicate possible delay/deficit. Bayley-III scores were measured at baseline and then again at study completion (180 days post randomization). The scores were calculated as a change between two time points (the Bayley-III value at 180 days minus the Bayley-III value at baseline). Secondary Outcome for 1st stage of project funded by Allen Foundation, Inc; Primary Outcome for 2nd stage of project funded by March of Dimes and Health Resources and Services Administration

Other

MeasureTime frameDescription
Long-term Efficacy in Improving CognitionLong-term effect (approximately 8 months) after intervention completionLong-term (26-32 months of age) cognitive outcome. This will be evaluated based on standard scores from the cognitive section of the Developmental Profile - 3. The range in standard scores is 40-140 with higher scores represent better cognitive ability.
Long-term Efficacy in Improving Executive Functions (BRIEF-P)Long-term effect (approximately 8 months) after intervention completionLong-term (26-32 months of age) executive function outcomes. This will be evaluated using scores on the Behavior Rating Inventory of Executive Function - Preschool Version (BRIEF-P). The BRIEF-P yields five clinical scales, each measuring a different aspect of executive function: inhibit, shift, emotional control, working memory, and plan/organize. The clinical scales merge to create four broad indices of executive function: inhibitory self-control, flexibility, emergent metacognition, and global executive composite. A t-score of 50 is equal to the population mean with scores below 50 indicating better executive function, and scores above 50 indicating worse executive function for each reported aspect.
Long-term Efficacy in Improving Executive Functions (CBCL)Long-term effect (approximately 8 months) after intervention completionLong-term (26-32 months of age) executive function outcomes. This will be evaluated using scores on the Attention Deficit/Hyperactivity Problems DSM oriented subscale and the Attention syndrome subscale of the Child Behavior Checklist 1.5-5 (CBCL). A t-score of 50 is equal to the population mean with scores below 50 indicating less behavioral problems, and scores above 50 indicating more behavioral problems.
Brief Infant Sleep Questionnaire (BISQ)Baseline to 180 days post-randomizationThe following sleep characteristics were captured based on caregiver-report: nocturnal sleep duration (hours), daytime sleep duration (hours), total sleep duration within a 24-hour period (hours). Larger values represent more time spent in each type of sleep. BISQ scores were measured at baseline and then again at study completion (180 days post randomization). The scores were calculated as a change between two time points (the BISQ value at 180 days minus the BISQ value at baseline).
Other Long-term Outcomes: LanguageLong-term effect (approximately 8 months) after intervention completionLong-term (26-32 months of age) outcomes. This will be evaluated using scores on the Communicative Development Inventory (CDI). On this measure, caregivers selected the number of words from a list of 100 common words that their child used. Scores reflect the total number of words, from the list of 100, that the child used.
Other Long-term Outcomes: Number of Participants With Developmental DelayLong-term effect (approximately 8 months) after intervention completionLong-term (26-32 months of age) outcomes. This will be evaluated using caregiver reports/diagnoses of developmental delay.
Other Long-term Outcomes: Number of Participants With Behavior DifficultiesLong-term effect (approximately 8 months) after intervention completionLong-term (26-32 months of age) outcomes. This will be evaluated using caregiver reports/diagnoses of behavioral difficulties.
Other Long-term Outcomes: Pervasive Developmental ProblemsLong-term effect (approximately 8 months) after intervention completionLong-term (26-32 months of age) outcomes. This will be evaluated using scores on the Pervasive Developmental Problems DSM oriented scale on the Child Behavior Checklist 1.5-5 (CBCL). A t-score of 50 is equal to the population mean with scores below 50 indicating less problems and scores above 50 indicating more problems.
Body CompositionBaseline to 180 days post-randomizationChanges in body composition from baseline to 6 months post-randomization (weight, recumbent length, head circumference, mid-upper arm circumference, triceps and subscapular skinfolds). These measurements were converted to z scores for corrected age based on Child Growth Standards from the World Health Organization. The z-score indicates the number of standard deviations away from the mean. A z score of 0 is equal to the mean of a reference population (children the same age and sex). Values less than 0 indicate values lower than the reference population, while values greater than 0 indicate values higher than the reference population.
Brief Infant Toddler Social Emotional Assessment (BITSEA)180 days post-randomizationBITSEA measures socioemotional development in toddlerhood. Scores were summed to provide competence (range: 0-22) and problem (range: 0-62) scores, respectively. The problem scale is further divided into subscales: externalizing (6 items; range: 0-12), internalizing (8 items; range: 0-16), and dysregulation (8 items; range: 0-16). Additionally, 14 items comprise a red flag scale (range: 0-28). Eight items from the competence and nine items from the problem subscales are indicative of behaviors often seen in children with ASD. Each of the 17 ASD items was dichotomized to illustrate the presence (1) (i.e., competence items absent, problem items present) or absence (0) (i.e., competence items present, problem items absent) of each ASD behavior. Items were then summed to derive an ASD score (range: 0-17). Higher competence scores represent better functioning, whereas higher problem (including the problem subscales), red flag, and ASD scores were indicative of poorer functioning.
Pervasive Developmental Disorders Screening Test - II, Stage 2 (PDDST-II)180 days post-randomizationThe PDDST-II is a clinically derived, caregiver-completed screener to assist in differentiating an ASD diagnosis from other disorders in children with developmental concerns, including those born preterm. The PDDST-II comprised 14 yes/no items that indicate the presence (1) or absence (0) of developmental concerns. Items were summed (possible range: 0-14) and higher scores represented greater developmental concern.
Other Long-term Outcomes: Sleep (BISQ)Long-term effect (approximately 8 months) after intervention completionLong-term (26-32 months of age) outcomes. This will be evaluated using scores on the Brief Infant Sleep Questionnaire (BISQ).The following sleep characteristics were captured based on caregiver-report: nocturnal sleep duration (hours), daytime sleep duration (hours), total sleep duration within a 24-hour period (hours). Larger values represent more time spent in each type of sleep. BISQ scores were measured at baseline and then again at post-intervention follow-up (approximately 8 months after the trial ended). The scores were calculated as a change between two time points (the BISQ value at post-intervention follow-up minus the BISQ value at baseline).
Other Long-term Outcomes: Sleep (CSHQ)Long-term effect (approximately 8 months) after intervention completionLong-term (26-32 months of age) outcomes. This will be evaluated using the total score on a subset of 13 items from the Children's Sleep Habits Questionnaire (CSHQ). The range in total score is 13-39. A higher score is indicative of more sleep problems.

Countries

United States

Participant flow

Participants by arm

ArmCount
Docosahexaenoic Acid + Arachidonic Acid
Docosahexaenoic Acid + Arachidonic Acid (DHA+AA) Docosahexaenoic Acid + Arachidonic Acid (DHA+AA): 200 mg DHA+ 200 mg AA per day for 6 months
189
Placebo
Corn oil supplement Placebo: 400 mg corn oil per day for 6 months
188
Total377

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyChange in Medical Care10
Overall StudyLost to Follow-up1416
Overall StudyWithdrawal by Subject51

Baseline characteristics

CharacteristicDocosahexaenoic Acid + Arachidonic AcidTotalPlacebo
Age, Continuous15.7 Months15.7 Months15.6 Months
Ethnicity (NIH/OMB)
Hispanic or Latino
7 Participants17 Participants10 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
182 Participants360 Participants178 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
2 Participants3 Participants1 Participants
Race (NIH/OMB)
Black or African American
52 Participants105 Participants53 Participants
Race (NIH/OMB)
More than one race
21 Participants33 Participants12 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
114 Participants236 Participants122 Participants
Region of Enrollment
United States
189 participants377 participants188 participants
Sex: Female, Male
Female
84 Participants182 Participants98 Participants
Sex: Female, Male
Male
105 Participants195 Participants90 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1890 / 188
other
Total, other adverse events
127 / 189129 / 188
serious
Total, serious adverse events
0 / 1890 / 188

Outcome results

Primary

Adherence

The mean (average) percentage of packets consumed by the children assigned to the supplement or placebo. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc

Time frame: Baseline to 180 days post-randomization

ArmMeasureValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic AcidAdherence80.6 average percentage of packets consumedStandard Deviation 28
PlaceboAdherence80.7 average percentage of packets consumedStandard Deviation 25
Primary

Enrollment and Trial Completion

The number of children who enroll in the trial and the number of those children who return for study visits 2 and 3. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc.

Time frame: Baseline to 180 days post-randomization

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Docosahexaenoic Acid + Arachidonic AcidEnrollment and Trial CompletionStudy Visit 2 Completion172 Participants
Docosahexaenoic Acid + Arachidonic AcidEnrollment and Trial CompletionStudy Visit 3 Completion166 Participants
PlaceboEnrollment and Trial CompletionStudy Visit 2 Completion163 Participants
PlaceboEnrollment and Trial CompletionStudy Visit 3 Completion168 Participants
Primary

Erythrocyte Fatty Acid Levels

This outcome measure involved an examination of change in plasma and RBC fatty acid concentrations from the first study visit to the final study visit. The changes were calculated as the fatty acid level at 180 days minus the fatty acid level at baseline. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc

Time frame: Baseline to 180 days post-randomization

Population: Rows titles are fatty acids with different C:D ratio where, C= Carbohydrate; D = Double bond; C:D is the ratio of the total amount of Carbon atoms of the fatty acid in relation to the number of double (unsaturated) bonds in it. Funding allotted for 205 children to be randomized to provide blood specimens but only 173 gave pre and post samples

ArmMeasureGroupValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic AcidErythrocyte Fatty Acid LevelsEicosapentaenoic acid (20:5n-3)0.0 nmol/mLStandard Deviation 0.1
Docosahexaenoic Acid + Arachidonic AcidErythrocyte Fatty Acid LevelsLinoleic acid (18:2n-6)-2.1 nmol/mLStandard Deviation 5.2
Docosahexaenoic Acid + Arachidonic AcidErythrocyte Fatty Acid LevelsDocosapentaenoic acid (22:5n-3)-0.1 nmol/mLStandard Deviation 0.1
Docosahexaenoic Acid + Arachidonic AcidErythrocyte Fatty Acid LevelsTotal n-60.2 nmol/mLStandard Deviation 6
Docosahexaenoic Acid + Arachidonic AcidErythrocyte Fatty Acid LevelsDocosahexaenoic acid (22:6n-3)1.1 nmol/mLStandard Deviation 1
Docosahexaenoic Acid + Arachidonic AcidErythrocyte Fatty Acid Levelsα-linolenic acid (18:3n-3)-0.1 nmol/mLStandard Deviation 0.4
Docosahexaenoic Acid + Arachidonic AcidErythrocyte Fatty Acid LevelsTotal n-30.9 nmol/mLStandard Deviation 1.1
Docosahexaenoic Acid + Arachidonic AcidErythrocyte Fatty Acid LevelsArachidonic acid (20:4n-6)2.0 nmol/mLStandard Deviation 2.6
PlaceboErythrocyte Fatty Acid LevelsTotal n-3-0.2 nmol/mLStandard Deviation 0.5
PlaceboErythrocyte Fatty Acid LevelsLinoleic acid (18:2n-6)0.6 nmol/mLStandard Deviation 4.4
PlaceboErythrocyte Fatty Acid LevelsArachidonic acid (20:4n-6)-0.2 nmol/mLStandard Deviation 1.1
PlaceboErythrocyte Fatty Acid Levelsα-linolenic acid (18:3n-3)0.0 nmol/mLStandard Deviation 0.3
PlaceboErythrocyte Fatty Acid LevelsEicosapentaenoic acid (20:5n-3)-0.1 nmol/mLStandard Deviation 0.2
PlaceboErythrocyte Fatty Acid LevelsDocosapentaenoic acid (22:5n-3)0.0 nmol/mLStandard Deviation 0.1
PlaceboErythrocyte Fatty Acid LevelsDocosahexaenoic acid (22:6n-3)-0.1 nmol/mLStandard Deviation 0.2
PlaceboErythrocyte Fatty Acid LevelsTotal n-60.4 nmol/mLStandard Deviation 5
Comparison: The change in erythrocyte fatty acids and the change in dietary DHA and EPA (aside from the supplement) were examined by treatment group using mixed effects regression, again with a random-effect for within-family dependence.p-value: <0.00195% CI: [-3.4, 0.9]Mixed Models Analysis
Comparison: The change in erythrocyte fatty acids and the change in dietary DHA and EPA (aside from the supplement) were examined by treatment group using mixed effects regression, again with a random-effect for within-family dependence.p-value: <0.00195% CI: [1.7, 2.8]Mixed Models Analysis
Comparison: The change in erythrocyte fatty acids and the change in dietary DHA and EPA (aside from the supplement) were examined by treatment group using mixed effects regression, again with a random-effect for within-family dependence.p-value: 0.6195% CI: [-1, 1.7]Mixed Models Analysis
Comparison: The change in erythrocyte fatty acids and the change in dietary DHA and EPA (aside from the supplement) were examined by treatment group using mixed effects regression, again with a random-effect for within-family dependence.p-value: 0.495% CI: [-0.1, 0.1]Mixed Models Analysis
Comparison: The change in erythrocyte fatty acids and the change in dietary DHA and EPA (aside from the supplement) were examined by treatment group using mixed effects regression, again with a random-effect for within-family dependence.p-value: 0.1295% CI: [0, 0.1]Mixed Models Analysis
Comparison: The change in erythrocyte fatty acids and the change in dietary DHA and EPA (aside from the supplement) were examined by treatment group using mixed effects regression, again with a random-effect for within-family dependence.p-value: <0.00195% CI: [-0.1, 0]Mixed Models Analysis
Comparison: The change in erythrocyte fatty acids and the change in dietary DHA and EPA (aside from the supplement) were examined by treatment group using mixed effects regression, again with a random-effect for within-family dependence.p-value: <0.00195% CI: [1, 1.5]Mixed Models Analysis
Comparison: The change in erythrocyte fatty acids and the change in dietary DHA and EPA (aside from the supplement) were examined by treatment group using mixed effects regression, again with a random-effect for within-family dependence.p-value: <0.00195% CI: [0.9, 1.4]Mixed Models Analysis
Primary

Erythrocyte Fatty Acid Levels (Additional Data)

This outcome measure involved an examination of change in plasma and RBC fatty acid concentrations from the first study visit to the final study visit. The changes were calculated as the fatty acid level at 180 days minus the fatty acid level at baseline. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc

Time frame: Baseline to 180 days post-randomization

Population: Rows titles are fatty acids with different C:D ratio where, C= Carbohydrate; D = Double bond; C:D is the ratio of the total amount of Carbon atoms of the fatty acid in relation to the number of double (unsaturated) bonds in it. Funding allotted for 205 children to be randomized to provide blood specimens but only 173 gave pre and post samples

ArmMeasureValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic AcidErythrocyte Fatty Acid Levels (Additional Data)-3.2 ratioStandard Deviation 3.9
PlaceboErythrocyte Fatty Acid Levels (Additional Data)1.6 ratioStandard Deviation 2.8
Comparison: The change in erythrocyte fatty acids and the change in dietary DHA and EPA (aside from the supplement) were examined by treatment group using mixed effects regression, again with a random-effect for within-family dependence.p-value: <0.00195% CI: [-5.5, -3.7]Mixed Models Analysis
Secondary

(Behavior) Infant Behavior Questionnaire-Revised (IBQ-R; Short Form)

Infant Behavior Questionnaire-Revised (IBQ-R; short form) was used to assess effortful control (12 items) and activity level (3 items). The IBQ-R measures early temperament-based inhibitory control,a key component of executive function as children mature. Scores range from 1 to 7, with higher scores indicating greater frequency of behaviors. IBQ-R scores were measured at baseline and then again at study completion (180 days post randomization). The scores were calculated as a change between two time points (the IBQ-R value at 180 days minus the IBQ-R value at baseline).

Time frame: Baseline to 180 days post-randomization

ArmMeasureGroupValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic Acid(Behavior) Infant Behavior Questionnaire-Revised (IBQ-R; Short Form)Activity Level0.6 units on a scaleStandard Deviation 1.5
Docosahexaenoic Acid + Arachidonic Acid(Behavior) Infant Behavior Questionnaire-Revised (IBQ-R; Short Form)Effortful Control-0.7 units on a scaleStandard Deviation 0.8
Placebo(Behavior) Infant Behavior Questionnaire-Revised (IBQ-R; Short Form)Effortful Control-0.5 units on a scaleStandard Deviation 0.8
Placebo(Behavior) Infant Behavior Questionnaire-Revised (IBQ-R; Short Form)Activity Level0.5 units on a scaleStandard Deviation 1.5
p-value: 0.13Mixed Models Analysis
p-value: 0.76Mixed Models Analysis
Secondary

(Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III)

Bayley Scales of Infant and Toddler Development, third edition, (Bayley-III) is an instrument designed to measure the developmental functioning of infants and toddlers between the ages of 1 month and 42 months (age adjustments for prematurity are accommodated with the tool). It provides age specific composite scores for cognitive (91 items,score min 55 max 145), language (98 items, score min 47 max 153), and motor (138 items, score min 46 max 154) skills. For all scales, higher scores are better and lower scores indicate possible delay/deficit. Bayley-III scores were measured at baseline and then again at study completion (180 days post randomization). The scores were calculated as a change between two time points (the Bayley-III value at 180 days minus the Bayley-III value at baseline). Secondary Outcome for 1st stage of project funded by Allen Foundation, Inc; Primary Outcome for 2nd stage of project funded by March of Dimes and Health Resources and Services Administration

Time frame: Baseline to 180 days post-randomization

ArmMeasureGroupValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic Acid(Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III)Cognitive Composite-2.6 units on a scaleStandard Deviation 13.3
Docosahexaenoic Acid + Arachidonic Acid(Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III)Language Composite-0.5 units on a scaleStandard Deviation 12
Docosahexaenoic Acid + Arachidonic Acid(Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III)Motor Composite-0.6 units on a scaleStandard Deviation 12.5
Placebo(Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III)Cognitive Composite-3.7 units on a scaleStandard Deviation 12.2
Placebo(Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III)Language Composite0.2 units on a scaleStandard Deviation 12.6
Placebo(Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III)Motor Composite-0.4 units on a scaleStandard Deviation 12.7
Comparison: A sample of 448 was planned to achieve \>80% power to detect a 4.2-point difference (0.27-standard deviation (SD)) in Bayley-III cognitive composite scores with 10% loss to follow-up.The investigational product manufacturer discontinued production once 377 were enrolled, thereby capping enrollment. That sample provided 80% power to detect a 0.29-SD difference in Bayley-III scores.p-value: 0.66Mixed Models Analysis
Comparison: A sample of 448 was planned to achieve \>80% power to detect a 4.2-point difference (0.27-standard deviation (SD)) in Bayley-III cognitive composite scores with 10% loss to follow-up.The investigational product manufacturer discontinued production once 377 were enrolled, thereby capping enrollment. That sample provided 80% power to detect a 0.29-SD difference in Bayley-III scores.p-value: 0.55Mixed Models Analysis
Comparison: A sample of 448 was planned to achieve \>80% power to detect a 4.2-point difference (0.27-standard deviation (SD)) in Bayley-III cognitive composite scores with 10% loss to follow-up.The investigational product manufacturer discontinued production once 377 were enrolled, thereby capping enrollment. That sample provided 80% power to detect a 0.29-SD difference in Bayley-III scores.p-value: 0.88Mixed Models Analysis
Other Pre-specified

Body Composition

Changes in body composition from baseline to 6 months post-randomization (weight, recumbent length, head circumference, mid-upper arm circumference, triceps and subscapular skinfolds). These measurements were converted to z scores for corrected age based on Child Growth Standards from the World Health Organization. The z-score indicates the number of standard deviations away from the mean. A z score of 0 is equal to the mean of a reference population (children the same age and sex). Values less than 0 indicate values lower than the reference population, while values greater than 0 indicate values higher than the reference population.

Time frame: Baseline to 180 days post-randomization

ArmMeasureGroupValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic AcidBody CompositionRecumbent Length0.1 z scoresStandard Deviation 0.9
Docosahexaenoic Acid + Arachidonic AcidBody CompositionMid-Upper Arm Circumference0.0 z scoresStandard Deviation 0.8
Docosahexaenoic Acid + Arachidonic AcidBody CompositionWeight0.1 z scoresStandard Deviation 0.4
Docosahexaenoic Acid + Arachidonic AcidBody CompositionTriceps Skinfold-0.0 z scoresStandard Deviation 0.7
Docosahexaenoic Acid + Arachidonic AcidBody CompositionHead Circumference-0.0 z scoresStandard Deviation 0.6
Docosahexaenoic Acid + Arachidonic AcidBody CompositionSubscapular Skinfold-0.2 z scoresStandard Deviation 0.8
PlaceboBody CompositionSubscapular Skinfold-0.2 z scoresStandard Deviation 0.9
PlaceboBody CompositionWeight0.0 z scoresStandard Deviation 0.4
PlaceboBody CompositionRecumbent Length0.2 z scoresStandard Deviation 0.9
PlaceboBody CompositionHead Circumference-0.1 z scoresStandard Deviation 0.5
PlaceboBody CompositionMid-Upper Arm Circumference0.1 z scoresStandard Deviation 0.7
PlaceboBody CompositionTriceps Skinfold-0.1 z scoresStandard Deviation 0.8
p-value: 0.99Mixed Models Analysis
p-value: 0.27Mixed Models Analysis
p-value: 0.39Mixed Models Analysis
p-value: 0.25Mixed Models Analysis
p-value: 0.85Mixed Models Analysis
p-value: 0.82Mixed Models Analysis
Other Pre-specified

Brief Infant Sleep Questionnaire (BISQ)

The following sleep characteristics were captured based on caregiver-report: nocturnal sleep duration (hours), daytime sleep duration (hours), total sleep duration within a 24-hour period (hours). Larger values represent more time spent in each type of sleep. BISQ scores were measured at baseline and then again at study completion (180 days post randomization). The scores were calculated as a change between two time points (the BISQ value at 180 days minus the BISQ value at baseline).

Time frame: Baseline to 180 days post-randomization

ArmMeasureGroupValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic AcidBrief Infant Sleep Questionnaire (BISQ)Nocturnal Sleep Duration0.25 hoursStandard Deviation 1.61
Docosahexaenoic Acid + Arachidonic AcidBrief Infant Sleep Questionnaire (BISQ)Daytime Sleep Duration-0.32 hoursStandard Deviation 1.15
Docosahexaenoic Acid + Arachidonic AcidBrief Infant Sleep Questionnaire (BISQ)Total Sleep Duration-0.07 hoursStandard Deviation 2.22
PlaceboBrief Infant Sleep Questionnaire (BISQ)Nocturnal Sleep Duration-0.16 hoursStandard Deviation 1.34
PlaceboBrief Infant Sleep Questionnaire (BISQ)Daytime Sleep Duration-0.46 hoursStandard Deviation 1.25
PlaceboBrief Infant Sleep Questionnaire (BISQ)Total Sleep Duration-0.57 hoursStandard Deviation 1.7
p-value: 0.11Mixed Models Analysis
p-value: 0.47Mixed Models Analysis
p-value: 0.32Mixed Models Analysis
Other Pre-specified

Brief Infant Toddler Social Emotional Assessment (BITSEA)

BITSEA measures socioemotional development in toddlerhood. Scores were summed to provide competence (range: 0-22) and problem (range: 0-62) scores, respectively. The problem scale is further divided into subscales: externalizing (6 items; range: 0-12), internalizing (8 items; range: 0-16), and dysregulation (8 items; range: 0-16). Additionally, 14 items comprise a red flag scale (range: 0-28). Eight items from the competence and nine items from the problem subscales are indicative of behaviors often seen in children with ASD. Each of the 17 ASD items was dichotomized to illustrate the presence (1) (i.e., competence items absent, problem items present) or absence (0) (i.e., competence items present, problem items absent) of each ASD behavior. Items were then summed to derive an ASD score (range: 0-17). Higher competence scores represent better functioning, whereas higher problem (including the problem subscales), red flag, and ASD scores were indicative of poorer functioning.

Time frame: 180 days post-randomization

Population: The number analyzed for the competence and ASD scales differs from the overall number analyzed due to missing data on these two scales.

ArmMeasureGroupValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic AcidBrief Infant Toddler Social Emotional Assessment (BITSEA)Externalizing2.29 units on a scaleStandard Deviation 2.06
Docosahexaenoic Acid + Arachidonic AcidBrief Infant Toddler Social Emotional Assessment (BITSEA)Dysregulation3.25 units on a scaleStandard Deviation 2.57
Docosahexaenoic Acid + Arachidonic AcidBrief Infant Toddler Social Emotional Assessment (BITSEA)Problem9.81 units on a scaleStandard Deviation 6.01
Docosahexaenoic Acid + Arachidonic AcidBrief Infant Toddler Social Emotional Assessment (BITSEA)Red Flag2.93 units on a scaleStandard Deviation 2.48
Docosahexaenoic Acid + Arachidonic AcidBrief Infant Toddler Social Emotional Assessment (BITSEA)Internalizing2.04 units on a scaleStandard Deviation 1.58
Docosahexaenoic Acid + Arachidonic AcidBrief Infant Toddler Social Emotional Assessment (BITSEA)ASD4.11 units on a scaleStandard Deviation 2.29
Docosahexaenoic Acid + Arachidonic AcidBrief Infant Toddler Social Emotional Assessment (BITSEA)Competence16.50 units on a scaleStandard Deviation 3.09
PlaceboBrief Infant Toddler Social Emotional Assessment (BITSEA)ASD4.36 units on a scaleStandard Deviation 2.98
PlaceboBrief Infant Toddler Social Emotional Assessment (BITSEA)Competence16.73 units on a scaleStandard Deviation 2.94
PlaceboBrief Infant Toddler Social Emotional Assessment (BITSEA)Problem10.18 units on a scaleStandard Deviation 6.84
PlaceboBrief Infant Toddler Social Emotional Assessment (BITSEA)Externalizing2.30 units on a scaleStandard Deviation 1.98
PlaceboBrief Infant Toddler Social Emotional Assessment (BITSEA)Internalizing2.31 units on a scaleStandard Deviation 2.1
PlaceboBrief Infant Toddler Social Emotional Assessment (BITSEA)Dysregulation3.29 units on a scaleStandard Deviation 2.59
PlaceboBrief Infant Toddler Social Emotional Assessment (BITSEA)Red Flag3.12 units on a scaleStandard Deviation 2.85
p-value: 0.42Mixed Models Analysis
p-value: 0.68Mixed Models Analysis
p-value: 0.78Mixed Models Analysis
p-value: 0.32Mixed Models Analysis
p-value: 0.97Mixed Models Analysis
p-value: 0.62Mixed Models Analysis
p-value: 0.69Mixed Models Analysis
Other Pre-specified

Long-term Efficacy in Improving Cognition

Long-term (26-32 months of age) cognitive outcome. This will be evaluated based on standard scores from the cognitive section of the Developmental Profile - 3. The range in standard scores is 40-140 with higher scores represent better cognitive ability.

Time frame: Long-term effect (approximately 8 months) after intervention completion

ArmMeasureValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic AcidLong-term Efficacy in Improving Cognition103.36 units on a scaleStandard Deviation 19
PlaceboLong-term Efficacy in Improving Cognition107.93 units on a scaleStandard Deviation 19.93
p-value: 0.09Mixed Models Analysis
Other Pre-specified

Long-term Efficacy in Improving Executive Functions (BRIEF-P)

Long-term (26-32 months of age) executive function outcomes. This will be evaluated using scores on the Behavior Rating Inventory of Executive Function - Preschool Version (BRIEF-P). The BRIEF-P yields five clinical scales, each measuring a different aspect of executive function: inhibit, shift, emotional control, working memory, and plan/organize. The clinical scales merge to create four broad indices of executive function: inhibitory self-control, flexibility, emergent metacognition, and global executive composite. A t-score of 50 is equal to the population mean with scores below 50 indicating better executive function, and scores above 50 indicating worse executive function for each reported aspect.

Time frame: Long-term effect (approximately 8 months) after intervention completion

ArmMeasureGroupValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic AcidLong-term Efficacy in Improving Executive Functions (BRIEF-P)Shift47.08 units on a scaleStandard Deviation 8.89
Docosahexaenoic Acid + Arachidonic AcidLong-term Efficacy in Improving Executive Functions (BRIEF-P)Inhibitory Self-control Index49.44 units on a scaleStandard Deviation 9.44
Docosahexaenoic Acid + Arachidonic AcidLong-term Efficacy in Improving Executive Functions (BRIEF-P)Working Memory53.79 units on a scaleStandard Deviation 11.3
Docosahexaenoic Acid + Arachidonic AcidLong-term Efficacy in Improving Executive Functions (BRIEF-P)Flexibility Index47.62 units on a scaleStandard Deviation 8.72
Docosahexaenoic Acid + Arachidonic AcidLong-term Efficacy in Improving Executive Functions (BRIEF-P)Emotional Control48.55 units on a scaleStandard Deviation 8.2
Docosahexaenoic Acid + Arachidonic AcidLong-term Efficacy in Improving Executive Functions (BRIEF-P)Emergent Metacognition Index52.17 units on a scaleStandard Deviation 11.27
Docosahexaenoic Acid + Arachidonic AcidLong-term Efficacy in Improving Executive Functions (BRIEF-P)Plan/Organize49.66 units on a scaleStandard Deviation 10.58
Docosahexaenoic Acid + Arachidonic AcidLong-term Efficacy in Improving Executive Functions (BRIEF-P)Global Executive Composite50.09 units on a scaleStandard Deviation 10.6
Docosahexaenoic Acid + Arachidonic AcidLong-term Efficacy in Improving Executive Functions (BRIEF-P)Inhibit50.20 units on a scaleStandard Deviation 10.69
PlaceboLong-term Efficacy in Improving Executive Functions (BRIEF-P)Global Executive Composite52.67 units on a scaleStandard Deviation 12.51
PlaceboLong-term Efficacy in Improving Executive Functions (BRIEF-P)Inhibit51.91 units on a scaleStandard Deviation 10.57
PlaceboLong-term Efficacy in Improving Executive Functions (BRIEF-P)Shift49.16 units on a scaleStandard Deviation 9.92
PlaceboLong-term Efficacy in Improving Executive Functions (BRIEF-P)Emotional Control49.98 units on a scaleStandard Deviation 9.33
PlaceboLong-term Efficacy in Improving Executive Functions (BRIEF-P)Working Memory56.04 units on a scaleStandard Deviation 13.63
PlaceboLong-term Efficacy in Improving Executive Functions (BRIEF-P)Plan/Organize52.69 units on a scaleStandard Deviation 12.02
PlaceboLong-term Efficacy in Improving Executive Functions (BRIEF-P)Inhibitory Self-control Index51.13 units on a scaleStandard Deviation 10.23
PlaceboLong-term Efficacy in Improving Executive Functions (BRIEF-P)Flexibility Index49.60 units on a scaleStandard Deviation 9.88
PlaceboLong-term Efficacy in Improving Executive Functions (BRIEF-P)Emergent Metacognition Index55.01 units on a scaleStandard Deviation 13.76
p-value: 0.29Mixed Models Analysis
p-value: 0.11Mixed Models Analysis
p-value: 0.23Mixed Models Analysis
p-value: 0.29Mixed Models Analysis
p-value: 0.06Mixed Models Analysis
p-value: 0.14Mixed Models Analysis
p-value: 0.13Mixed Models Analysis
p-value: 0.16Mixed Models Analysis
Other Pre-specified

Long-term Efficacy in Improving Executive Functions (CBCL)

Long-term (26-32 months of age) executive function outcomes. This will be evaluated using scores on the Attention Deficit/Hyperactivity Problems DSM oriented subscale and the Attention syndrome subscale of the Child Behavior Checklist 1.5-5 (CBCL). A t-score of 50 is equal to the population mean with scores below 50 indicating less behavioral problems, and scores above 50 indicating more behavioral problems.

Time frame: Long-term effect (approximately 8 months) after intervention completion

ArmMeasureGroupValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic AcidLong-term Efficacy in Improving Executive Functions (CBCL)Attention Deficit/Hyperactivity Problems55.04 t-scoreStandard Deviation 6.9
Docosahexaenoic Acid + Arachidonic AcidLong-term Efficacy in Improving Executive Functions (CBCL)Attention Problems55.21 t-scoreStandard Deviation 7.1
PlaceboLong-term Efficacy in Improving Executive Functions (CBCL)Attention Deficit/Hyperactivity Problems55.08 t-scoreStandard Deviation 6.43
PlaceboLong-term Efficacy in Improving Executive Functions (CBCL)Attention Problems55.71 t-scoreStandard Deviation 6.82
p-value: 0.98Mixed Models Analysis
p-value: 0.67Mixed Models Analysis
Other Pre-specified

Other Long-term Outcomes: Language

Long-term (26-32 months of age) outcomes. This will be evaluated using scores on the Communicative Development Inventory (CDI). On this measure, caregivers selected the number of words from a list of 100 common words that their child used. Scores reflect the total number of words, from the list of 100, that the child used.

Time frame: Long-term effect (approximately 8 months) after intervention completion

ArmMeasureValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic AcidOther Long-term Outcomes: Language56.68 wordsStandard Deviation 28.75
PlaceboOther Long-term Outcomes: Language61.15 wordsStandard Deviation 27.94
p-value: 0.2Mixed Models Analysis
Other Pre-specified

Other Long-term Outcomes: Number of Participants With Behavior Difficulties

Long-term (26-32 months of age) outcomes. This will be evaluated using caregiver reports/diagnoses of behavioral difficulties.

Time frame: Long-term effect (approximately 8 months) after intervention completion

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Docosahexaenoic Acid + Arachidonic AcidOther Long-term Outcomes: Number of Participants With Behavior Difficulties5 Participants
PlaceboOther Long-term Outcomes: Number of Participants With Behavior Difficulties1 Participants
95% CI: [0.52, 39.15]
Other Pre-specified

Other Long-term Outcomes: Number of Participants With Developmental Delay

Long-term (26-32 months of age) outcomes. This will be evaluated using caregiver reports/diagnoses of developmental delay.

Time frame: Long-term effect (approximately 8 months) after intervention completion

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Docosahexaenoic Acid + Arachidonic AcidOther Long-term Outcomes: Number of Participants With Developmental Delay30 Participants
PlaceboOther Long-term Outcomes: Number of Participants With Developmental Delay18 Participants
95% CI: [0.8, 3.32]
Other Pre-specified

Other Long-term Outcomes: Pervasive Developmental Problems

Long-term (26-32 months of age) outcomes. This will be evaluated using scores on the Pervasive Developmental Problems DSM oriented scale on the Child Behavior Checklist 1.5-5 (CBCL). A t-score of 50 is equal to the population mean with scores below 50 indicating less problems and scores above 50 indicating more problems.

Time frame: Long-term effect (approximately 8 months) after intervention completion

ArmMeasureValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic AcidOther Long-term Outcomes: Pervasive Developmental Problems53.76 t-scoreStandard Deviation 6.12
PlaceboOther Long-term Outcomes: Pervasive Developmental Problems55.54 t-scoreStandard Deviation 7.78
p-value: 0.047Mixed Models Analysis
Other Pre-specified

Other Long-term Outcomes: Sleep (BISQ)

Long-term (26-32 months of age) outcomes. This will be evaluated using scores on the Brief Infant Sleep Questionnaire (BISQ).The following sleep characteristics were captured based on caregiver-report: nocturnal sleep duration (hours), daytime sleep duration (hours), total sleep duration within a 24-hour period (hours). Larger values represent more time spent in each type of sleep. BISQ scores were measured at baseline and then again at post-intervention follow-up (approximately 8 months after the trial ended). The scores were calculated as a change between two time points (the BISQ value at post-intervention follow-up minus the BISQ value at baseline).

Time frame: Long-term effect (approximately 8 months) after intervention completion

ArmMeasureGroupValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic AcidOther Long-term Outcomes: Sleep (BISQ)Nocturnal Sleep Duration-0.11 hoursStandard Deviation 1.68
Docosahexaenoic Acid + Arachidonic AcidOther Long-term Outcomes: Sleep (BISQ)Daytime Sleep Duration-0.46 hoursStandard Deviation 1.3
Docosahexaenoic Acid + Arachidonic AcidOther Long-term Outcomes: Sleep (BISQ)Total Sleep Duration-0.57 hoursStandard Deviation 2.2
PlaceboOther Long-term Outcomes: Sleep (BISQ)Nocturnal Sleep Duration-0.38 hoursStandard Deviation 1.43
PlaceboOther Long-term Outcomes: Sleep (BISQ)Daytime Sleep Duration-0.81 hoursStandard Deviation 1.41
PlaceboOther Long-term Outcomes: Sleep (BISQ)Total Sleep Duration-1.17 hoursStandard Deviation 1.85
p-value: 0.23Mixed Models Analysis
p-value: 0.07Mixed Models Analysis
p-value: 0.06Mixed Models Analysis
Other Pre-specified

Other Long-term Outcomes: Sleep (CSHQ)

Long-term (26-32 months of age) outcomes. This will be evaluated using the total score on a subset of 13 items from the Children's Sleep Habits Questionnaire (CSHQ). The range in total score is 13-39. A higher score is indicative of more sleep problems.

Time frame: Long-term effect (approximately 8 months) after intervention completion

ArmMeasureValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic AcidOther Long-term Outcomes: Sleep (CSHQ)18.82 units on a scaleStandard Deviation 4.96
PlaceboOther Long-term Outcomes: Sleep (CSHQ)19.57 units on a scaleStandard Deviation 5.4
p-value: 0.51Mixed Models Analysis
Other Pre-specified

Pervasive Developmental Disorders Screening Test - II, Stage 2 (PDDST-II)

The PDDST-II is a clinically derived, caregiver-completed screener to assist in differentiating an ASD diagnosis from other disorders in children with developmental concerns, including those born preterm. The PDDST-II comprised 14 yes/no items that indicate the presence (1) or absence (0) of developmental concerns. Items were summed (possible range: 0-14) and higher scores represented greater developmental concern.

Time frame: 180 days post-randomization

ArmMeasureValue (MEAN)Dispersion
Docosahexaenoic Acid + Arachidonic AcidPervasive Developmental Disorders Screening Test - II, Stage 2 (PDDST-II)2.91 units on a scaleStandard Deviation 2.35
PlaceboPervasive Developmental Disorders Screening Test - II, Stage 2 (PDDST-II)3.37 units on a scaleStandard Deviation 3.02
p-value: 0.22Mixed Models Analysis

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026